Topics

CORRECTING and REPLACING XPOVIO™ (selinexor) Available for Order at Biologics by McKesson

18:07 EDT 12 Jul 2019 | Businesswire
Biologics by McKesson

FDA-approved drug is new treatment option for patients with relapsed or penta-refractory multiple myeloma

First sentence of second paragraph of release dated July 8, 2019 should read: “XPOVIO is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory or intolerant to at least two proteasome inhibitors (PI), at least two immunomodulatory agents (IMiD), and an anti-CD38 monoclonal antibody (mAb).1,2 "

The corrected release reads:

XPOVIO™(SELINEXOR) AVAILABLE FOR ORDER AT BIOLOGICS BY MCKESSON

FDA-approved drug is new treatment option for patients with relapsed or penta-refractory multiple myeloma

Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO™ (selinexor).

XPOVIO is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory or intolerant to at least two proteasome inhibitors (PI), at least two immunomodulatory agents (IMiD), and an anti-CD38 monoclonal antibody (mAb).1,2 Approved on July 3, XPOVIO was previously granted both Orphan Drug designation and Fast Track designation by the FDA.

“We are excited that Biologics is included in the limited network distribution for XPOVIO,” said Ann Steagall, director of Clinical Policy at Biologics. “We are pleased to be included in the distribution of a first in class XPO inhibitor. Patients who have exhausted the current standard of care therapies now have another option. It is important to us as a premier oncology pharmacy to offer patients and prescribers the newest therapies available.”

Biologics is committed to and recognized for its high level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes a pharmacist with in-depth knowledge of disease states and oncology therapies available, an experienced oncology nurse and a financial counselor who is familiar with various financial assistance programs and organizations that help cancer patients. This highly-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with over 25 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics by McKesson delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics by McKesson harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

1BRAND NAME (selinexor) [package insert].

2Data on file. Karyopharm Therapeutics.

McKesson
Claire Crye, Public Relations
281.825.9927 claire.crye@mckesson.com

NEXT ARTICLE

More From BioPortfolio on "CORRECTING and REPLACING XPOVIO™ (selinexor) Available for Order at Biologics by McKesson"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...